

Anti-IL-1a & IL1b Antibody (Lutikizumab)

Introduction

Lutikizumab (ABT-981) is an anti-IL-1 α and IL-1 β bivariate domain immunoglobulin. Lutikizumab binds and inhibits IL-1 α and IL-1 β . Lutikizumab can be used in osteoarthritis research.

Product parameters

Alternative Names	ABT-981
Target Accession	P01583 & P01584
Target	IL-1a & IL1b
CAS number	1791411-57-8
Molecular Weight	196.8 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human IL 1a, Fc at 2 ug/mL can bind Anti-IL-1a & IL1b Reference Antibody (Lutikizumab), EC50=0.0294 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

